DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021071/S-050
NDA 021410/S-039
NDA 021700/S-022

SUPPLEMENT APPROVAL

SmithKline Beecham(Cork) Ltd d/b/a GlaxoSmithKline
Attention: Linda Rebar
Director, Global Regulatory Affairs
1250 South Collegeville Road
PO Box 5089, Mail Code UP4400
Collegeville, PA 19426-0989

Dear Ms. Rebar:

Please refer to your supplemental New Drug Applications (sNDAs) dated and received April 15, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for:

NDA Number	Supplement Number	Product Name
NDA 021071	S-050	Avandia (rosiglitazone maleate) tablets
NDA 021410	S-039	Avandamet (rosiglitazone maleate and metformin hydrochloride) tablets
NDA 021700	S-022	Avandaryl (rosiglitazone maleate and glimepiride) tablets

We acknowledge receipt of your risk evaluation and mitigation strategy (REMS) assessment dated and received April 15, 2015. We also acknowledge our REMS Assessment Acknowledgment letter issued on July 10, 2015.

These supplemental new drug applications propose that FDA no longer require a REMS for rosiglitazone-containing products.

APPROVAL

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Avandamet (rosiglitazone maleate/metformin hydrochloride) and Avandaryl (rosiglitazone maleate/glimepiride) were originally approved on December 2, 2008; and the

REMS for Avandia was originally approved on May 18, 2011. These REMS were modified and converted to a single, shared system REMS for branded and generic rosiglitazone-containing products, approved on January 25, 2013. The most recent modification of the single, shared system REMS was approved on May 7, 2014. The single, shared system REMS consists of an element to assure safe use, which is to provide training on the current state of knowledge concerning the cardiovascular risk of rosiglitazone-containing products to health care providers likely to prescribe rosiglitazone-containing products, and a timetable for submission of assessments of the REMS.

Your proposed modifications to the REMS consist of elimination of the element to assure safe use and, therefore, release from the requirement for the REMS for rosiglitazone-containing products.

We have determined that an element to assure safe use is no longer necessary because your REMS assessment submitted on April 15, 2015 showed that training on the current state of knowledge concerning the cardiovascular risk of rosiglitazone-containing products to health care providers likely to prescribe rosiglitazone-containing products was provided. Additionally, since the May 7, 2014, REMS modification, FDA has not become aware of any new data suggesting a potential increased risk of ischemic cardiovascular events.

Therefore, because an element to assure safe use is no longer necessary to ensure that the benefits outweigh the risks, a REMS is no longer required for rosiglitazone-containing products.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Liz Godwin, Regulatory Project Manager, at (240) 402-3438.

Sincerely,

{See appended electronic signature page}

Jennifer Rodriguez Pippins, M.D., M.P.H.
Deputy Director for Safety
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JENNIFER R PIPPINS
12/16/2015